| Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) (NCT05164055) | Genzyme, a Sanofi Company | 2022-07-11 |
| Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (NCT04910776) | Sanofi | 2021-09-01 |
| Higher Dose of Alglucosidase Alpha for Pompe Disease (NCT05017402) | Taipei Veterans General Hospital, Taiwan | 2021-09-01 |
| A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) (NCT04093349) | Spark Therapeutics, Inc. | 2020-10-01 |
| Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment (NCT03687333) | Genzyme, a Sanofi Company | 2018-12-04 |
| Biomarker for Glycogen Storage Diseases (BioGlycogen) (NCT02385162) | CENTOGENE GmbH Rostock | 2018-08-20 |
| Respiratory Muscle Training in L-Onset Pompe Disease (LOPD) (NCT02801539) | Duke University | 2017-02-02 |
| Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT (NCT02761421) | Taipei Veterans General Hospital, Taiwan | 2016-01-01 |
| Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy (NCT02635269) | Rigshospitalet, Denmark | 2016-01-01 |
| High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease (NCT01656590) | Columbia University | 2012-10-01 |
| An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease (NCT00701129) | Genzyme, a Sanofi Company | 2009-10-01 |
| A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease (NCT00515398) | Amicus Therapeutics | 2007-08-01 |
| Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease (NCT00074932) | Genzyme, a Sanofi Company | 2004-11-01 |
| Pompe Disease Registry Protocol (NCT00231400) | Genzyme, a Sanofi Company | 2004-09-15 |
| A Prospective, Observational Study in Patients With Late-Onset Pompe Disease (NCT00077662) | Genzyme, a Sanofi Company | 2004-03-01 |
| Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease (NCT00074919) | Genzyme, a Sanofi Company | 2003-12-01 |
| Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies (NCT00763932) | Genzyme, a Sanofi Company | 2003-04-01 |
| A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease (NCT00059280) | Genzyme, a Sanofi Company | 2003-04-01 |
| rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease) (NCT00053573) | Genzyme, a Sanofi Company | 2003-02-01 |
| A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II (NCT00051935) | Genzyme, a Sanofi Company | 2003-01-01 |
| Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease (NCT00025896) | Genzyme, a Sanofi Company | 2001-05-01 |
| Genetic and Family Studies of Inherited Muscle Diseases (NCT00001331) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1993-05-01 |